Compare Globus Medical Inc. Class A Common Stock (GMED) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs abrdn Physical Palladium Shares ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while abrdn Physical Palladium Shares ETF trades at $20.15 (market cap $602.28M). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 17× abrdn Physical Palladium Shares ETF's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and abrdn Physical Palladium Shares ETF for 34 Days on average.
| GMED | PALL | |
|---|---|---|
Market Cap | $10.25B | $602.28M |
Volume | 1,108,124 | 499,677 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $96.82 | $37.18 |
52-Week Low | $58.33 | $19.83 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
PALL trades at $20.38, down 1.12% with a bearish technical signal from moving averages. The ETF shows oversold conditions with RSI readings below 30, while palladium prices remain 47% below January 2026 highs. Recent news highlights potential catch-up opportunities as platinum and palladium have lagged the broader precious metals rally.
The outlook suggests contrarian opportunity as palladium approaches technical support levels, though fundamental data remains limited. Key risks include continued commodity price pressure and industrial demand uncertainty, while potential catalysts include supply constraints and renewed institutional interest in undervalued precious metals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
